ATRA - Atara Biotherapeutics Inc
Atara Biotherapeutics Inc Logo

ATRA - Atara Biotherapeutics Inc

https://www.atarabio.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.

52W High
$18.70
52W Low
$5.00
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.22
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
17.93
Forward P/E (<15 better)
3.63
EV/EBITDA (<8 favorable)
6.01
EV/Revenue (<3 favorable)
0.46
P/S (TTM) (<3 favorable)
0.48
P/B (<3 favorable)
1.97
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
21.29%
Institutions (25–75% balanced)
45.69%
Shares Outstanding
7,023,000
Float
4,422,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
188,667,000
Gross Profit (TTM)
5,544,000
EPS (TTM)
0.72
Profit Margin (>10% good)
0.03%
Operating Margin (TTM) (higher better)
0.27%
ROE (TTM) (>15% strong)
-20.15%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.39
Momentum
Bearish momentum
Value
0.2930
Previous
0.3222
Trend
Falling
Signal Cross
No cross
As of
Sep. 11, 2025